Management ChangeJun 1, 2026, 08:37 AM
Aditxt Appoints Jeffrey M. Busch as Interim CEO; Multiple Leadership Changes
AI Summary
Aditxt, Inc. announced significant leadership changes, including the resignation of CEO Amro Albanna, Director Shahrokh Shabahang, and COO Rowena Albanna. The Board appointed Jeffrey M. Busch as Interim Chief Executive Officer, effective May 31, 2026. Mr. Busch, previously CEO of Aditxt's subsidiary Ignite Proteomics, brings extensive experience from founding and leading Global Medical REIT Inc. to over $1 billion enterprise value. Brian Brady was also appointed non-executive Chairman of the Board. Under Mr. Busch, Aditxt will focus on patient-first innovation, revenue-driven growth for Ignite Proteomics, stakeholder responsibility, and capital market engagement.
Key Highlights
- Amro Albanna resigned as CEO and Director of Aditxt, Inc., effective May 31, 2026.
- Shahrokh Shabahang resigned as a Director, effective May 31, 2026, but remains Chief Innovation Officer.
- Rowena Albanna resigned as Chief Operating Officer, effective June 5, 2026.
- Jeffrey M. Busch was appointed Interim Chief Executive Officer, effective May 31, 2026.
- Mr. Busch previously founded and led Global Medical REIT Inc. to over $1 billion in enterprise value.
- His interim employment arrangement includes an annual base salary of $500,000.
- Brian Brady was appointed non-executive Chairman of the Board, effective May 31, 2026.
- New strategic priorities include revenue-driven innovation for Ignite Proteomics and capital market engagement.
Price Impact
More from ADTX